Adjuvants are components of vaccines used to potentiate their immunogenicity and protective efficacy. Several adjuvants from different origins, compositions, and types have been approved for their use in animals and humans; many more are under research and development around the globe. Greater efforts are needed to develop vaccines for diseases that lack them, even those not yet in clinical trials, and to enhance our understanding of selecting appropriate adjuvants and the immune molecular mechanisms they trigger. In addition, specific adjuvants are needed for parenteral or mucosal vaccines, which leads to diverse challenging issues. Those aspects are crucial and therefore transdisciplinary approaches have given innovative adjuvant prototypes. The broad integrated knowledge of adjuvants from in silico design, biological (microbial, plants, animals), and chemical, among other origins, composed of unique or multiple molecules, and for application through parenteral or mucosal routes, have enabled benefits and will continue doing so for humankind.
Diseases have been a serious concern since ancient times. Preventive and therapeutic vaccines have saved millions of people through affordable vaccination programs. In this regard, adjuvants have played a crucial role in the successful protective efficacy of vaccines since their incorporation a century ago. Therefore, research and development of adjuvants have progressed from the initial simple preparations to immunoinformatic-assisted AI, new methods of chemical synthesis (molecules, nanoparticles, composites), and novel prokaryotic and eukaryotic sources that concurrent into the scientific knowledge on the best routes for administration to save lives. This research topic aims to integrate and discuss emerging advances in the research and development of novel adjuvants, as well as to highlight the expanding knowledge in the context of immunity and vaccinology for the prevention, control, and treatment of diseases affecting both animals and humans.
This research topic is an open space to offer novel, revolutionary, and cutting-edge scientific findings on adjuvants, deciphering their design, origin, type, and efficacy, as well as to improve the understanding of their mechanisms of action. We intend to integrate a global concern and show the efforts of the scientific community to fight disease for animals and humans, analyzing the knowledge obtained so far and the gaps in adjuvants in authorized vaccines, as well as those in clinical and non-clinical trials, and in proof of concept. In addition, we hope to open the discussion on the most recent concepts on the immune response involved in adjuvants and the paths to take to improve the potency and effectiveness of vaccines.
We encourage scientists to contribute with the following article types: original research, review, mini-review, perspective, and opinion. Contributions are welcomed regarding one, but not limited to, the following research fields:
· Immunoinformatic-assisted AI design of adjuvants
· Chemical synthesis of adjuvants
· Nanoadjuvants
· Immunology of adjuvants
· Routes of administration of adjuvants
· Preventive and therapeutic efficacy of adjuvants
The topic editors confirm that they have no conflicts of interest in relation to the editorship and publication of this collection.
Keywords:
adjuvant, ai, nanoadjuvants, therapeutics, Vaccines
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Adjuvants are components of vaccines used to potentiate their immunogenicity and protective efficacy. Several adjuvants from different origins, compositions, and types have been approved for their use in animals and humans; many more are under research and development around the globe. Greater efforts are needed to develop vaccines for diseases that lack them, even those not yet in clinical trials, and to enhance our understanding of selecting appropriate adjuvants and the immune molecular mechanisms they trigger. In addition, specific adjuvants are needed for parenteral or mucosal vaccines, which leads to diverse challenging issues. Those aspects are crucial and therefore transdisciplinary approaches have given innovative adjuvant prototypes. The broad integrated knowledge of adjuvants from in silico design, biological (microbial, plants, animals), and chemical, among other origins, composed of unique or multiple molecules, and for application through parenteral or mucosal routes, have enabled benefits and will continue doing so for humankind.
Diseases have been a serious concern since ancient times. Preventive and therapeutic vaccines have saved millions of people through affordable vaccination programs. In this regard, adjuvants have played a crucial role in the successful protective efficacy of vaccines since their incorporation a century ago. Therefore, research and development of adjuvants have progressed from the initial simple preparations to immunoinformatic-assisted AI, new methods of chemical synthesis (molecules, nanoparticles, composites), and novel prokaryotic and eukaryotic sources that concurrent into the scientific knowledge on the best routes for administration to save lives. This research topic aims to integrate and discuss emerging advances in the research and development of novel adjuvants, as well as to highlight the expanding knowledge in the context of immunity and vaccinology for the prevention, control, and treatment of diseases affecting both animals and humans.
This research topic is an open space to offer novel, revolutionary, and cutting-edge scientific findings on adjuvants, deciphering their design, origin, type, and efficacy, as well as to improve the understanding of their mechanisms of action. We intend to integrate a global concern and show the efforts of the scientific community to fight disease for animals and humans, analyzing the knowledge obtained so far and the gaps in adjuvants in authorized vaccines, as well as those in clinical and non-clinical trials, and in proof of concept. In addition, we hope to open the discussion on the most recent concepts on the immune response involved in adjuvants and the paths to take to improve the potency and effectiveness of vaccines.
We encourage scientists to contribute with the following article types: original research, review, mini-review, perspective, and opinion. Contributions are welcomed regarding one, but not limited to, the following research fields:
· Immunoinformatic-assisted AI design of adjuvants
· Chemical synthesis of adjuvants
· Nanoadjuvants
· Immunology of adjuvants
· Routes of administration of adjuvants
· Preventive and therapeutic efficacy of adjuvants
The topic editors confirm that they have no conflicts of interest in relation to the editorship and publication of this collection.
Keywords:
adjuvant, ai, nanoadjuvants, therapeutics, Vaccines
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.